Lumos Pharma
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4200 Marathon Blvd Ste 200, Austin, Texa...Phone Number
(512) 215-2630Website
www.lumos-pharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Lumos Pharma
Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this mission and a strategy that is grounded upon time and cost-efficient drug development to deliver safe and effective therapies to patients.Explore more
Lumos Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lumos Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Lumos Pharma
Earning: See what the market has to say on Lumos Pharma recently announced quarterly report
Funding: Get notified immidiatlly once Lumos Pharma has new funding data
Click to see if Lumos Pharma had a recent Job posting/layoffs
Product Launch: Get notified when Lumos Pharma launches new products
Lumos Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Lumos Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Lumos Pharma is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Lumos Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to Lumos Pharma
Compare insights from companies similar to Lumos Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lumos Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lumos Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lumos Pharma.
Lumos Pharma financials insights
Gather financial insights about Lumos Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$13M
2016
Series B
$34M
Lumos Pharma Tech Stack
A closer look at the technologies used by Lumos Pharma
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Earnings
Lumos Pharma has recently released 2024 Q1 report with the following insight: Trial execution risks, including ability to enroll trial on timelines. Mitigation strategies in place to expand trial globally.
Earnings
Lumos Pharma has recently released 2024 Q1 report with the following insight: Currently no funds to finance Phase 3 trial, but confidence is high that financing can be secured.
Financial Planning, Funding
Earnings
Lumos Pharma News & Media
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK.Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK.ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.
NEW YORK, Oct. 23, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Lumos Pharma, Inc. (NASDAQ: LUMO) and its board of directors concerning the proposed acquisition of the company by Double Point Ventures LLC. Stockholders will receive $4.25 and...LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lumos Pharma, Inc. (NASDAQ: LUMO) to Double Point Ventures LLC for $4.25 per share in cash, plus one non-transferable, unsecured Contingent Value Right per share payable on achievement of certain milestones, is fair to Lumos shareholders. Halper Sadeh encourages Lumos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lumos Pharma
Sign Up For FreeTo access detailed company insights
Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this mission and a strategy that is grounded upon time and cost-efficient drug development to deliver safe an... Read More
